Concomitant use of parenterally administered midazolam with telaprevir increased exposure to midazolam. Co-administration should be done in a setting which ensures clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
Dose reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.
Co-administration of oral midazolam with telaprevir is contraindicated. |
|
zolpidem (non-benzodiazepine sedative)* |
↓ zolpidem |
Exposure to zolpidem was decreased when co-administered with telaprevir. Clinical monitoring and dose titration of zolpidem is recommended to achieve the desired clinical response. |
|
CALCIUM CHANNEL BLOCKERS |
|
amlodipine* |
↑ amlodipine
|
Exposure to amlodipine was increased when co-administered with telaprevir. Caution should be used and dose reduction for amlodipine should be considered. Clinical monitoring is recommended. |
diltiazem
felodipine
nicardipine
nifedipine
nisoldipine
verapamil |
↑ calcium channel blockers |
Concentrations of other calcium channel blockers may be increased when telaprevir is co-administered. Caution is warranted and clinical monitoring of patients is recommended. |
|
CORTICOSTEROIDS |
Systemic
prednisone
methylprednisolone |
↑ prednisone
↑ methylprednisolone |
Systemic corticosteroids such as prednisone and methylprednisolone are CYP3A substrates. Since telaprevir is a potent CYP3A inhibitor, plasma concentrations of these corticosteroids can be increased significantly. Co-administration of systemic corticosteroids and telaprevir is not recommended [see Warnings and Precautions (5.3)]. |
Systemic
dexamethasone |
↓ telaprevir |
Systemic dexamethasone induces CYP3A and can thereby decrease telaprevir plasma concentrations. This may result in loss of therapeutic effect of telaprevir. Therefore this combination should be used with caution or alternatives should be considered. |
Inhaled/Nasal
fluticasone
budesonide |
↑ fluticasone
↑ budesonide |
Concomitant use of inhaled fluticasone or budesonide and telaprevir may increase plasma concentrations of fluticasone or budesonide resulting in significantly reduced serum cortisol concentrations. Co-administration of fluticasone or budesonide and telaprevir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. |
|
ENDOTHELIN RECEPTOR ANTAGONIST |
|
bosentan |
↑ bosentan |
Concentrations of bosentan may be increased when co-administered with telaprevir. Caution is warranted and clinical monitoring is recommended. |
|
HIV-ANTIVIRAL AGENTS: HIV-PROTEASE INHIBITORS (PIs) |
